



US 20100104504A1

(19) **United States**(12) **Patent Application Publication**
Echeverria Moran(10) **Pub. No.: US 2010/0104504 A1**(43) **Pub. Date: Apr. 29, 2010**(54) **MATERIALS AND METHODS FOR
DIAGNOSIS, PREVENTION AND/OR
TREATMENT OF STRESS DISORDERS AND
CONDITIONS ASSOCIATED WITH ABETA
PEPTIDE AGGREGATION**(75) Inventor: **Valentina Echeverria Moran,**
Largo, FL (US)

Correspondence Address:

**SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
PO Box 142950
GAINESVILLE, FL 32614 (US)**(73) Assignees: **University of South Florida,**
Tampa, FL (US); **United States**
Department of Veterans Affairs,
Washington, DC (US)(21) Appl. No.: **12/586,681**(22) Filed: **Sep. 24, 2009****Related U.S. Application Data**(60) Provisional application No. 61/194,064, filed on Sep.
24, 2008, provisional application No. 61/099,746,
filed on Sep. 24, 2008.**Publication Classification**(51) **Int. Cl.****A61K 51/00** (2006.01)**A61K 31/4439** (2006.01)**A61P 25/28** (2006.01)**A61P 25/26** (2006.01)**C07D 401/00** (2006.01)(52) **U.S. Cl. 424/1.11; 514/343; 424/1.81; 546/278.4**(57) **ABSTRACT**

The subject invention concerns materials and methods for treating and/or preventing diseases associated with accumulation of A β peptide in neural tissue. The subject invention also concerns materials and methods for treating and/or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and/or treat Alzheimer's disease, Parkinson's disease, and/or Down's syndrome. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant.

The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of A β peptide in neural tissue, such as Alzheimer's disease and Parkinson's disease, using the chemical cotinine. In one embodiment, the method comprises administering cotinine labeled with a detectable label to a person or animal. The presence of labeled cotinine in neural tissue is then determined. The level and/or location of cotinine can be analyzed and a diagnosis made. The subject invention also concerns cotinine labeled with a detectable label. In one embodiment, the cotinine is labeled with a radioisotope that can be detected by Positron Emission Tomography (PET) or single photon emission computed tomography (SPECT).